Aytu BioScience is a drug manufacturers - specialty & generic business based in the US. Aytu BioScience shares (AYTU) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $1.51 – a decrease of 2.7% over the previous week. Aytu BioScience employs 102 staff and has a trailing 12-month revenue of around $81 million.
Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.
Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.
| Latest market close | $1.51 |
|---|---|
| 52-week range | $1.49 - $3.45 |
| 50-day moving average | $2.22 |
| 200-day moving average | $2.71 |
| Wall St. target price | $8.00 |
| PE ratio | N/A |
| Dividend yield | N/A |
| Earnings per share (TTM) | $-2.86 |
The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.
This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.
Historical closes compared with the close of $1.49 from 2024-11-20
| 1 week (2024-11-15) | -3.87% |
|---|---|
| 1 month (2024-10-23) | -30.18% |
| 3 months (2024-08-22) | -39.68% |
| 6 months (2024-05-22) | -52.27% |
| 1 year (2023-11-22) | -40.64% |
|---|---|
| 2 years (2022-11-22) | -66.21% |
| 3 years (2021-11-22) | 39 |
| 5 years (2019-11-22) | 144 |
Valuing Aytu BioScience stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Aytu BioScience's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.
Aytu BioScience's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $6.1 million.
The EBITDA is a measure of a Aytu BioScience's overall financial performance and is widely used to measure a its profitability.
| Revenue TTM | $81 million |
|---|---|
| Gross profit TTM | $66.6 million |
| Return on assets TTM | -1.06% |
| Return on equity TTM | -47.24% |
| Profit margin | -19.56% |
| Book value | $4.64 |
| Market Capitalization | $9.5 million |
TTM: trailing 12 months
We're not expecting Aytu BioScience to pay a dividend over the next 12 months.
Aytu BioScience's shares were split on a 1:20 basis on 5 January 2023 . So if you had owned 20 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Aytu BioScience shares – just the quantity. However, indirectly, the new 1900% higher share price could have impacted the market appetite for Aytu BioScience shares which in turn could have impacted Aytu BioScience's share price.
Over the last 12 months, Aytu BioScience's shares have ranged in value from as little as $1.489 up to $3.45. A popular way to gauge a stock's volatility is its "beta".
Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Aytu BioScience's is -1.402. This would suggest that Aytu BioScience's shares have been inversely-correlated to the average (for this exchange) – so when the broader market trended up or down, Aytu BioScience has bucked the trend.
Aytu BioPharma, Inc. , a pharmaceutical company, focuses on commercializing novel therapeutics drugs in the United States and internationally. The company offers prescription products for the treatment of attention deficit hyperactivity disorder (ADHD), including Adzenys XR-ODT for patients from six years of age and above, and Cotempla XR-ODT for patients from six to seventeen years old. It also provides pediatric prescription product portfolio comprising Karbinal ER, an extended-release carbinoxamine (antihistamine) suspension indicated to treat numerous allergic conditions for patients two years and above; and Poly-Vi-Flor and Tri-Vi-Flor complementary prescription fluoride-based multi-vitamin products containing combinations of fluoride and vitamins in liquid and chewable tablet form for infants and children with fluoride deficiency. The company was formerly known as Aytu BioScience, Inc. and changed its name to Aytu BioPharma, Inc. in March 2021.
Robinhood Launches Presidential Election Event Contracts Ahead of the Nov 5 Presidential Election
Explore the best bonuses for opening a new brokerage account.
These are the best trading platforms for beginners, according to Finder’s comprehensive analysis.
Compare pros, cons, research tools and reviews for these two trading platforms.
Check out our picks of the best trading apps for beginners, options traders, hands-off investors and more.
See our picks of the best brokerage accounts, including Fidelity, SoFi, Charles Schwab, Public, Robinhood and E*TRADE .
What you need to know about investing in the leading indicator for the overall US stock market.
Maximize $10,000 with broker bonuses, IRA contribution matches, index funds, stocks, ladder CDs, hiring a financial advisor and more.
Top ways to invest $20K include stocks, retirement accounts, conservative investments, ETFs and more. See our full list here.
A deep dive into the highlights and limitations of Robinhood.